Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer

• मुख्य लेखकों: Xiaomin Wan (लेखक), Xiaohui Zeng (लेखक), Liubao Peng (लेखक), Ye Peng (लेखक), Qiao Liu (लेखक), Lidan Yi (लेखक), Xia Luo (लेखक), Qijian Deng (लेखक), Chongqing Tan (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Frontiers Media S.A., 2021-08-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Objective: This study evaluated the cost-effectiveness of nivolumab plus ipilimumab vs. chemotherapy in the first-line setting for patients with advanced non-small-cell lung cancer (NSCLC) from the US payer perspective.Materials and methods: A Markov model wasdeveloped to evaluate the cost and effec...